ABIVAX SUCCESSFULLY COMPLETES FIRST-IN-MAN STUDY OF ABX464, A HIGHLY DIFFERENTIATED SMALL MOLECULE TARGETING HIV
ABIVAX SUCCESSFULLY COMPLETES FIRST-IN-MAN STUDY OF ABX464, A HIGHLY DIFFERENTIATED SMALL MOLECULE TARGETING HIV
December 1, 2014
- Details
- Published on Monday, 01 December 2014 14:02
ABIVAX today announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.
AXB464 is a novel, small molecule with the potential to inhibit HIV replication. Through its unique mode of action, ABX464 is the first anti-HIV drug able to induce a long-lasting HIV viral load reduction even after treatment has been stopped, in pre-clinical testing in mice.